Back Article

Alt M, Renz R, Hofschneider P H. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides[J]. Hepatology, 1995, 22(): 707-717.

Anderson W F. Human gene therapy[J]. Science, 1992, 256(): 808-813. doi: 10.1126/science.1589762

Baltimore D. Intracellular immunization[J]. Nature, 1988, 325(): 395-396.

Barajas M, Mazzolini G, Genove G. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12[J]. Hepatology, 2001, 33(): 52-61. doi: 10.1053/jhep.2001.20796

Bartholomew R M, Carmichael E P, Findeis M A. Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks[J]. J Viral Hepatitis, 1995, 2(): 273-278. doi: 10.1111/jvh.1995.2.issue-6

Beck J, Nassal M. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells[J]. Nucl Acids Res, 1995, 23(): 4954-4962. doi: 10.1093/nar/23.24.4954

Bilheimer D W, Goldstein J L, Grundy S M. Liver transplantation to provide low density lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia[J]. N Engl J Med, 1984, 311(): 1658-1664. doi: 10.1056/NEJM198412273112603

Blau H M, Springer M L. Muscle mediated gene therapy[J]. N Engl J Med, 1995, 333(): 1554-1556. doi: 10.1056/NEJM199512073332308

Blum H E, Galun E, Weizs cker F. Inhibition of hepatitis B virus by antisense oligodeoxy-nucleotides[J]. Lancet, 1991, 337(): 1230-.

Branch A D. A hitchhiker's guide to antisense and nonantisense biochemical pathways[J]. Hepatology, 1996, 24(): 1517-1529. doi: 10.1002/(ISSN)1527-3350

Brown M S, Goldstein J L. A receptor-mediated pathway for cholesterol homeostasis[J]. Science, 1986, 232(): 34-37. doi: 10.1126/science.3513311

Butterfield L H. Immunotherapeutic strategies for hepatocellular carcinoma[J]. Gastroenterology, 2004, 127(): S232-241. doi: 10.1053/j.gastro.2004.09.038

Butterfield L H, Meng W S, Koh A. T cell responses to HLA-A*0201-restricted peptides derived fromhuman alpha fetoprotein[J]. J Immunol, 2001, 166(): 5300-5308. doi: 10.4049/jimmunol.166.8.5300

Calabretta B. Inhibition of protooncogene expres-sion by antisense oligodeoxynucleotides: biological and therapeutic implications[J]. Cancer Res, 1991, 51(): 4505-4510.

Cao G, Kuriyama S, Du P. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer[J]. Gastroenterology, 1997, 112(): 501-510. doi: 10.1053/gast.1997.v112.pm9024304

Chow Y H, Huang W L, Chi W K. Imp-rovement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2[J]. J Virol, 1997, 71(): 169-178.

Davis G L. Treatment of chronic hepatitis B (editorial; comment)[J]. Hepatology, 1991, 14(): 567-569. doi: 10.1002/(ISSN)1527-3350

Davis H L, Mancini M, Michel M L. DNA-mediated immunization to hepatitis B surface antigen-longevity of primary response and effect of boost[J]. Vaccine, 1996, 14(): 910-915. doi: 10.1016/0264-410X(95)00255-Y

Davis H L, McCluskie M J, Gerin J L. DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines[J]. Proc Natl Acad Sci USA, 1996, 93(): 7213-7218. doi: 10.1073/pnas.93.14.7213

Davis H L, Schirmbeck R, Reimann J. DNA-mediated immunization in mice induces a potent MHC class Ⅰ-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein[J]. Human Gene Therapy, 1995, 6(): 1447-1456. doi: 10.1089/hum.1995.6.11-1447

Delaney M A, Goyal S, Seeger C. 1991. Design of modified core genes that inhibit replication of woodchuck hepatitis virus. In: , Viral hepatitis and liver disease (Hollinger F B, Lemon S M, Margolis H. ed. ). Williams & Wilkins, Baltimore, Maryland. p 667-668.

Dougherty W G, Parks T D. 1995. Transgenes and gene suppression: telling us something new? Curr Opin Cell Biol, 7: 399-405.

Dykxhoorn D M, Lieberman J. The silent revo-lution: RNA interference as basic biology, research tool, and therapeutic[J]. Annu Rev Med, 2005, 56(): 401-423. doi: 10.1146/annurev.med.56.082103.104606

Folgori A, Capone S, Ruggeri L. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees[J]. Nat Med, 2006, 12(): 190-197. doi: 10.1038/nm1353

Forns X, Payette P J, Ma X.. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV[J]. Hepatology, 2000, 32(): 618-625.

Fox I J, Chowdhury J R, Kaufman S S. Treatment of the Crigler-Najjar syndrome type Ⅰ with hepatocyte transplantation[J]. N Engl J Med, 1998, 338(): 1422-1426. doi: 10.1056/NEJM199805143382004

Friedmann T. Progress toward human gene therapy[J]. Science, 1989, 244(): 1275-1281. doi: 10.1126/science.2660259

Geissler M, Mohr L, Weth R. Immuno-therapy directed against alpha-fetoprotein results in autoimmune liver disease during liver regeneration in mice[J]. Gastroenterology, 2001, 121(): 931-939. doi: 10.1053/gast.2001.28019

Giladi H, Ketzinel-Gilad M, Rivkin L. Small interfering RNA inhibits hepatitis B virus replication in mice[J]. Mol Ther, 2003, 8(): 769-776. doi: 10.1016/S1525-0016(03)00244-2

Goodarzi G, Gross S C, Tewari A. Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen[J]. J Gen Virol, 1990, 71(): 3021-3025. doi: 10.1099/0022-1317-71-12-3021

Grimm C F, Ortmann D, Mohr L. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice[J]. Gastroenterology, 2000, 119(): 1104-1112. doi: 10.1053/gast.2000.18157

Grimm D, Streetz K L, Jopling C L. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways[J]. Nature, 2006, 441(): 537-541. doi: 10.1038/nature04791

Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1[J]. Semin Liver Dis, 2001, 21(): 563-571. doi: 10.1055/s-2001-19035

Grossman M, Rader D J, Muller D W M. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia[J]. NatureMedicine, 1995, 1(): 1148-1154.

Grossman M, Raper S E, Kozarsky K. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia[J]. Nat Genet, 1994, 6(): 335-341. doi: 10.1038/ng0494-335

Gutierrez A A, Lemoine N R, Sikora K. Gene therapy for cancer[J]. Lancet, 1992, 339(): 715-721. doi: 10.1016/0140-6736(92)90606-4

Habib N, Salama H, Abd El Latif Abu Median A. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma[J]. Cancer Gene Ther, 2002, 9(): 254-259. doi: 10.1038/sj.cgt.7700431

Hallenbeck P L, Chang Y N, Hay C. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma[J]. Hum Gene Ther, 1999, 10(): 1721-1733. doi: 10.1089/10430349950017725

Hanecak R, Brown-Driver V, Fox M C. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes[J]. J Virol, 1996, 70(): 5203-5212.

Haseloff J, Gerlach W L. Simple RNA enzymes with new and highly specific endoribonuclease activities[J]. Nature, 1988, 334(): 585-591. doi: 10.1038/334585a0

Heise C, Sampson-Johannes A, Williams A. 1997. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents[J]. Nature Med, 1997, 3(): 639-645. doi: 10.1038/nm0697-639

Helene C. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides[J]. Eur J Cancer, 1991, 27(): 1466-1471. doi: 10.1016/0277-5379(91)90033-A

Helene C, Toulme J J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids[J]. Biochim Biophys Acta, 1990, 1049(): 99-125. doi: 10.1016/0167-4781(90)90031-V

Herschkowitz I. Functional inactivation of genes by dominant negative mutations[J]. Nature, 1987, 329(): 219-222. doi: 10.1038/329219a0

Hoeg J M, Starzl T E, Brewer H B. Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia[J]. Am J Card, 1987, 59(): 705-707. doi: 10.1016/0002-9149(87)91199-4

Huang H, Chen S H, Kosai K. Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo[J]. Gene Therapy, 1996, 3(): 980-987.

Ido A, Nakata K, Kato Y. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter[J]. Cancer Research, 1995, 55(): 3105-3109.

Ishikawa H, Nakao K, Matsumoto K. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene[J]. Hepatology, 2003, 37(): 696-704. doi: 10.1053/jhep.2003.50077

Iwashita Y, Tahara K, Goto S. A Phase Ⅱ study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer[J]. Cancer Immunol Immunother, 2003, 52(): 155-161.

Jones J T, Lee S W, Sullenger B A. Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells[J]. Nature Med, 1996, 2(): 643-648. doi: 10.1038/nm0696-643

Kanai F, Lan K H, Shiratori Y. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene[J]. Cancer Res, 1997, 57(): 461-465.

Kanai F, Shiratori Y, Yoshida Y. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene[J]. Hepatology, 1996, 23(): 1359-1368.

Kaneko S, Hallenbeck P, Kotani T. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression[J]. Cancer Research, 1995, 55(): 5283-5287.

Kapadia S B, Brideau-Andersen A, Chisari F V. Interference of hepatitis C virus RNA replication by short interfering RNAs[J]. Proc Natl Acad Sci USA, 2003, 100(): 2014-2018. doi: 10.1073/pnas.252783999

Kay M A, Manno C S, Ragni M V. Evidence for gene transfer and expression of factor Ⅸ in haemophilia B patients treated with an AAV vector[J]. Nat Genet, 2000, 24(): 257-261. doi: 10.1038/73464

Kitabwalla M, Ruprecht R M. RNA interference-a new weapon against HIV and beyond[J]. N Engl J Med, 2002, 347(): 1364-1367. doi: 10.1056/NEJMcibr022294

Klein C, Bock C T, Wedemeyer H. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA[J]. Gastroenterology, 2003, 125(): 9-18. doi: 10.1016/S0016-5085(03)00720-0

Konishi M, Wu C H, Wu G Y. Inhibition of HBV replication by siRNA in a stable HBV-producing cell line[J]. Hepatology, 2003, 38(): 842-850. doi: 10.1002/(ISSN)1527-3350

Kren B T, Parashar B, Bandyopadhyay P. Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type Ⅰ with a chimeric oligonucleotide[J]. Proc Natl Acad Sci USA, 1999, 96(): 10349-10354. doi: 10.1073/pnas.96.18.10349

Kroger A, Ortmann D, Krohne T U. Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in mice[J]. Cancer Res, 2001, 61(): 2609-2617.

Krohne T U, Shankara S, Geissler M. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro[J]. Hepatology, 2001, 34(): 511-518. doi: 10.1053/jhep.2001.26749

Kuhöber A, Pudollek H P, Reifenberg K. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice[J]. J Immunol, 1996, 156(): 3687-3695.

Kuriyama S, Nakatani T, Masui K. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma[J]. Hepatology, 1995, 22(): 1838-1846.

Lagging L M, Meyer K, Hoft D. Immune responses to plasmid DNA encoding the hepatitis C virus core protein[J]. J Virol, 1995, 69(): 5859-5863.

Lan N, Howrey R P, Lee S-W. Ribozyme-mediated repair of sickle -globin mRNAs in erythrocyte precursors[J]. Science, 1998, 280(): 1593-1596. doi: 10.1126/science.280.5369.1593

Lieber A, He C-Y, Polyak S J. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes[J]. J Virol, 1996, 70(): 8782-8791.

Liu B L, Robinson M, Han Z Q. ICP34[J]. 5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther, 2003, 10(): 292-303.

Lowe S W. Progress of the smart bomb cancer virus[J]. Nature Med, 1997, 3(): 606-608. doi: 10.1038/nm0697-606

Major M E, Vitvitski L, Mink M A. DNA based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid[J]. J Virol, 1995, 69(): 5798-5805.

Mancini M, Hadchouel M, Davis H L. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state[J]. Proc Natl Acad Sci USA, 1996, 93(): 12496-12501. doi: 10.1073/pnas.93.22.12496

McCaffrey A P, Nakai H, Pandey K. Inhibition of hepatitis B virus in mice by RNA interference[J]. Nat Biotechnol, 2003, 21(): 639-644. doi: 10.1038/nbt824

McDonnell W M, Askari F K. DNA vaccines[J]. N Engl J Med, 1996, 334(): 42-45. doi: 10.1056/NEJM199601043340110

Michel M L, Davis H L, Schleef M. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans[J]. Proc Natl Acad Sci USA, 1995, 92(): 5307-5311. doi: 10.1073/pnas.92.12.5307

Miller A D. Human gene therapy comes of age[J]. Nature, 1992, 357(): 455-460. doi: 10.1038/357455a0

Mizutani T, Kato N, Hirota M. Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells[J]. Biochem Biophys Res Commun, 1995, 212(): 906-911. doi: 10.1006/bbrc.1995.2055

Mohr L, Shankara S, Yoon S K. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene[J]. Hepatology, 2000, 31(): 606-614. doi: 10.1002/(ISSN)1527-3350

Morgan R A, Anderson W F. Human gene therapy[J]. Annu Rev Biochem, 1993, 62(): 191-217. doi: 10.1146/annurev.bi.62.070193.001203

Mulligan R C. The basic science of gene therapy[J]. Science, 1993, 260(): 926-932. doi: 10.1126/science.8493530

Muraca M, Gerunda G, Neri D. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a[J]. Lancet, 2002, 359(): 317-318. doi: 10.1016/S0140-6736(02)07529-3

Nakazono K, Ito Y, Wu C H. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro[J]. Hepatology, 1996, 23(): 1297-1303.

Offensperger W B, Offensperger S, Walter E. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides[J]. EMBO J, 1993, 12(): 1257-1262.

Overturf K, Al-Dhalimy M, Tanguay R. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type Ⅰ[J]. Nat Genet, 1996, 12(): 266-273. doi: 10.1038/ng0396-266

Pardoll D M, Beckerleg A. M. Exposing the immunology of naked DNA vaccines[J]. Immunity, 1995, 3(): 165-169. doi: 10.1016/1074-7613(95)90085-3

Pawlik T M, Nakamura H, Yoon S S. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus[J]. Cancer Res, 2000, 60(): 2790-2795.

Pei Z, Chu L, Zou W. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice[J]. Hepatology, 2004, 39(): 1371-1381. doi: 10.1002/(ISSN)1527-3350

Qian C, Drozdzik M, Caselmann W H. The potential of gene therapy in the treatment of hepatocellular carcinoma[J]. J Hepatol, 2000, 32(): 344-351. doi: 10.1016/S0168-8278(00)80082-3

Randall G, Grakoui A, Rice C M. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs[J]. Proc Natl Acad Sci USA, 2003, 100(): 235-240. doi: 10.1073/pnas.0235524100

Rosenberg S A. Gene therapy for cancer[J]. JAMA, 1992, 268(): 2416-2419. doi: 10.1001/jama.1992.03490170088031

Roth D A, Tawa N E, Jr O'Brien J M. Nonviral transfer of the gene encoding coagulation factor Ⅷ in patients with severe hemophilia A[J]. N Engl J Med, 2001, 344(): 1735-1742. doi: 10.1056/NEJM200106073442301

Sakamoto N, Wu C H, Wu G Y. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes[J]. J Clin Invest, 1996, 98(): 2720-2728. doi: 10.1172/JCI119097

Sangro B, Mazzolini G, Ruiz J. Phase Ⅱ trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors[J]. J Clin Oncol, 2004, 22(): 1389-1397. doi: 10.1200/JCO.2004.04.059

Sarver N, Cairns S. Ribozyme trans-splicing and RNA tagging: Following the messenger[J]. Nature Med, 1996, 2(): 641-642. doi: 10.1038/nm0696-641

Scaglioni P, Melegari M, Takahashi M. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents[J]. Hepatology, 1996, 24(): 1010-1017. doi: 10.1002/(ISSN)1527-3350

Scaglioni P P, Melegari M, Wands J R. Characterization of hepatitis B virus core mutants that inhibit viral replication[J]. Virology, 1994, 205(): 112-120. doi: 10.1006/viro.1994.1625

Schirmbeck R, Bohm W, Ando K. Nucleic acid vaccination primes hepatitis B virus surface antigen specific cytotoxic T lymphocytes in nonresponder mice[J]. J Virol, 1995, 69(): 5929-5934.

Seki T, Kiyosawa K, Inoko H. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients[J]. Hepatology, 1990, 12(): 1300-1304. doi: 10.1002/(ISSN)1527-3350

Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference[J]. Hepatology, 2003, 37(): 764-770. doi: 10.1053/jhep.2003.50146

Taylor J A, Naoumov N V. The potential of RNA interference as a tool in the management of viral hepatitis[J]. J Hepatol, 2005, 42(): 139-144.

Thompson J D, Macejak D, Couture L. Ribozymes in gene therapy[J]. Nature Med, 1995, 1(): 277-278. doi: 10.1038/nm0395-277

Tseng B Y, Brown K D. Antisense oligonucleotide technology in the development of cancer therapeutics[J]. Cancer Gene Ther, 1994, 1(): 65-71.

Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase[J]. Science, 1990, 249(): 505-510. doi: 10.1126/science.2200121

Uprichard S L, Boyd B, Althage A. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs[J]. Proc Natl Acad Sci USA, 2005, 102(): 773-778. doi: 10.1073/pnas.0409028102

Vidalin O, Major M E, Rayner B. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides[J]. Antimicrobial Agents & Chemotherapy, 1996, 40(): 2337-2344.

Vitiello A, Ishioka G, Grey H M. Development of a lipopeptide based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans[J]. J Clin Invest, 1995, 95(): 341-349.

von Weizsäcker F, Blum H E, Wands J R. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template[J]. Biochem Biophys Res Commun, 1992, 189(): 743-748. doi: 10.1016/0006-291X(92)92264-X

von Weizsäcker F, Wieland S, Blum H E. Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein[J]. Hepatology, 1996, 24(): 294-299.

Wagner R W. Gene inhibition using antisense oligodeoxynucleotides[J]. Nature, 1994, 372(): 333-335. doi: 10.1038/372333a0

Wakita T, Wands J R. Specific inhibition of hepatitis C virus expression by antisense oligodeoxy-nucleotides[J]. In vitro model for selection of target sequence. J Biol Chem, 1994, 269(): 14205-14210.

Wands J R, Lavaissiere L, Moradpour D. Immunological approach to hepatocellular carcinoma[J]. Journal of Viral Hepatitis, 1997, 4(Suppl. 2): 60-74.

Welch P J, Tritz R, Yei S. A potential therapeutic application of hairpin ribozymes -in vitro and in vivo studies of gene therapy for hepatitis C virus infection[J]. Gene Therapy, 1996, 3(): 994-1001.

Williams B R. Targeting specific cell types with silencing RNA[J]. N Engl J Med, 2005, 353(): 1410-1411. doi: 10.1056/NEJMcibr052492

Wills K N, Huang W M, Harris M P. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene[J]. Cancer Gene Therapy, 1995, 2(): 191-197.

Wilson J A, Jayasena S, Khvorova A. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells[J]. Proc Natl Acad Sci USA, 2003, 100(): 2783-2788. doi: 10.1073/pnas.252758799

Wu G Y, Wu C H. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides[J]. J Biol Chem, 1992, 267(): 12436-12439.

Xu G W, Sun Z T, Forrester K. Tissue-specific growth suppression and chemosensitivity prom-otion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene[J]. Hepatology, 1996, 24(): 1264-1268. doi: 10.1002/(ISSN)1527-3350

Yao Z, Zhou Y, Feng X. In vivo inhibition of hepatitis B viral gene expression by antisense phosphoro-thioate oligodeoxynucleotides in athymic nude mice[J]. J Viral Hepatitis, 1996, 3(): 19-22. doi: 10.1111/jvh.1996.3.issue-1

Ying C, De Clercq E, Neyts J. Selective inhibition of hepatitis B virus replication by RNA interference[J]. Biochem Biophys Res Commun, 2003, 309(): 482-484. doi: 10.1016/j.bbrc.2003.08.021

Zender L, Kock R, Eckhard M. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors[J]. Gastroen-terology, 2002, 123(): 608-618. doi: 10.1053/gast.2002.34756